{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:17:48Z","timestamp":1792711068713,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment of advanced renal cell carcinoma has changed dramatically since 2005 with the approval of 12 regimens including oral, intravenous, and combination strategies. These approvals have changed the treatment paradigm for these patients and developed new challenges and a critical role for oncology nurses to ensure that the treatment plan and adverse events are managed effectively. The majority of these regimens include an oral anticancer drug, which requires patients and their caregivers to understand the medication, the potential adverse events, the importance of medicine adherence, and the importance of early and ongoing education with the oncology team to maximize clinical outcomes. The evolution of the role of the nurse in meeting this need and its critical contribution to the comprehensive care of the kidney cancer patient will be reviewed.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000476","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:36:38Z","timestamp":1600302998000},"page":"460-463","source":"Crossref","is-referenced-by-count":9,"title":["The Critical Role of the Oncology Nurse as a Partner in the Management of Patients With Advanced Kidney Cancer"],"prefix":"10.1097","volume":"26","author":[{"given":"Nancy P.","family":"Moldawer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","year":"1995","journal-title":"J Clin Oncol"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1078-0432.CCR-14-1520","article-title":"The high-dose aldesleukin \u201cselect\u201d trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma","volume":"21","year":"2015","journal-title":"Clin Cancer Res"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1188\/14.CJON.637-640","article-title":"Chemotherapy education for patients with cancer: a literature review","volume":"18","year":"2014","journal-title":"Clin J Oncol Nurs"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/2277-9531.171782","article-title":"Effect of self-care education on the quality of life in patients with breast cancer","volume":"4","year":"2015","journal-title":"J Educ Health Promot"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.3747\/co.22.2366","article-title":"Relationships between patient knowledge and the severity of side effects, daily nutrient intake, psychological status, and performance status in lung cancer patients","volume":"22","year":"2015","journal-title":"Curr Oncol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.hoc.2011.05.004","article-title":"Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices","volume":"25","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.soncn.2011.02.005","article-title":"Interventions to promote adherence with oral agents","volume":"27","year":"2011","journal-title":"Semin Oncol Nurs"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","article-title":"Ipilimumab and its toxicities: a multidisciplinary approach","volume":"18","year":"2013","journal-title":"Oncologist"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.soncn.2011.02.003","article-title":"The challenges of oral agents as antineoplastic treatments","volume":"27","year":"2011","journal-title":"Semin Oncol Nurs"},{"key":"bib10-20230924","first-page":"87","article-title":"Promoting oral therapy adherence","volume":"21","year":"2017","journal-title":"Clin J Oncol Nurs"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cmonc.2011.11.002","article-title":"Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management","volume":"9","year":"2012","journal-title":"Community Oncol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","year":"2017","journal-title":"J Immunother Cancer"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1503\/cmaj.180870","article-title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","volume":"191","year":"2019","journal-title":"CMAJ"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"bib15-20230924","first-page":"271","article-title":"Immune checkpoint inhibitor therapy: key principles when educating patients","volume":"23","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","year":"2019","journal-title":"J Immunother Cancer"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","year":"1999","journal-title":"J Clin Oncol"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study","volume":"14","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T22:56:56Z","timestamp":1723589816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000476"}},"subtitle":["Toxicity Management, Symptom Control, and Palliative Care"],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000476","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}